Exelixis, Inc. (EXEL): Price and Financial Metrics
EXEL Price/Volume Stats
| Current price | $23.70 | 52-week high | $24.34 |
| Prev. close | $23.53 | 52-week low | $18.08 |
| Day low | $23.36 | Volume | 1,560,800 |
| Day high | $23.76 | Avg. volume | 2,255,849 |
| 50-day MA | $22.73 | Dividend yield | N/A |
| 200-day MA | $21.87 | Market Cap | 6.99B |
EXEL Stock Price Chart Interactive Chart >
Exelixis, Inc. (EXEL) Company Bio
Exelixis is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. The company was founded in 1994 and is based in San Francisco, California.
Latest EXEL News From Around the Web
Below are the latest news stories about EXELIXIS INC that investors may wish to consider to help them evaluate EXEL as an investment opportunity.
11 Stocks Insiders and Billionaires Are Crazy AboutIn this article, we will take a detailed look at the 11 Stocks Insiders and Billionaires Are Crazy About. For a quick overview of such stocks, read our article 5 Stocks Insiders and Billionaires Are Crazy About. In his famous book titled One Up on Wall Street, Peter Lynch talks about how average investors miss out on opportunities by […] |
Is the Options Market Predicting a Spike in Exelixis (EXEL) Stock?Investors need to pay close attention to Exelixis (EXEL) stock based on the movements in the options market lately. |
Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report?Beam Therapeutics Inc. (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023ALAMEDA, Calif., December 07, 2023--Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast the Exelixis 2023 R&D Day: Science & Strategy event taking place on Tuesday, December 12, 2023, from 9:00 a.m. to 12:30 p.m. EST. During the event, featured speakers will review the progress of the company’s growing research and development pipeline, highlight recent clinical updates and elaborate on the company’s continued efforts to serve more patients with cancer and generate sustainable, lo |
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study DataUpdates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week. |
EXEL Price Returns
| 1-mo | -0.13% |
| 3-mo | 7.14% |
| 6-mo | 17.09% |
| 1-year | 29.51% |
| 3-year | -4.24% |
| 5-year | 18.56% |
| YTD | -1.21% |
| 2023 | 49.56% |
| 2022 | -12.25% |
| 2021 | -8.92% |
| 2020 | 13.90% |
| 2019 | -10.42% |
Continue Researching EXEL
Here are a few links from around the web to help you further your research on Exelixis Inc's stock as an investment opportunity:Exelixis Inc (EXEL) Stock Price | Nasdaq
Exelixis Inc (EXEL) Stock Quote, History and News - Yahoo Finance
Exelixis Inc (EXEL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...